CA2413835A1 - Isolation and culturing of fetal cells - Google Patents
Isolation and culturing of fetal cells Download PDFInfo
- Publication number
- CA2413835A1 CA2413835A1 CA002413835A CA2413835A CA2413835A1 CA 2413835 A1 CA2413835 A1 CA 2413835A1 CA 002413835 A CA002413835 A CA 002413835A CA 2413835 A CA2413835 A CA 2413835A CA 2413835 A1 CA2413835 A1 CA 2413835A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- maternal
- fetal
- antibodies
- fetal cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Ecology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a method for isolating fetal cells from maternal blood, wherein the blood sample has not been substantially enriched, such as by performing, on a sample of maternal blood from which at the most 50 % of the anucleated material cells thereof and/or at the most 50 % of the nucleated maternal cells thereof have been removed, selective labelling of fetal cells in the maternal blood sample, identifying the selectively labelled fetal cells, and specifically isolating substantially only the selectively labelled fetal cells. The selective labelling may be conducted with antibodies specific for the fetal cells and/or probes hybridising for example with fetal mRNA. Also, the invention relates to a method of diagnosing a disease in a fetus wherein the specifically labelling may then be conducted with a marker, such as a probe, to a gene or a gene mutation specific for the genetic disease or a chromosome abnormality to be diagnosed.
Description
Title Isolation and culturing of fetal cells.
Introduction The present invention relates to a method for isolating fetal cells from maternal blood, in particular from maternal blood not having been subjected to concentration or enrichment.
In addition the invention relates to a method for culturing fetal cells.
Background The examination of fetal cells for early detection of fetal diseases and genetic ab-normalities is carried out in connection with many pregnancies, in particular when the maternal age is high (35 years or above) or where genetic diseases are known in the family. Fetal cells may be obtained by amniocentesis, the removal of amniotic fluid from the amniotic cavity within the amniotic sac or by chorion biopsy, where biopsies are taken from the placenta, a so-called invasive sampling.
During pregnancy a variety of cell types of fetal origin cross the placenta and circu-late within maternal peripheral blood. The feasability of using fetal cells in the ma-ternal circulation for diagnostic purposes has been hindered by the fact that fetal cells are present in maternal blood in only very limited numbers, reported numbers have been from 1:105 to 1:108 fetal cells per nucleated maternal cells. In addition most fetal cells cannot be distinguished from maternal cells on the basis of morphol-ogy alone, but rather must be identified based upon detection of fetal cell markers.
However, it would be advantageously to perform fetal diagnosis by a non-invasive procedure, such as a maternal blood sample.
One particular fetal cell type within maternal blood that has been demonstrated to be useful for detecting fetal DNA is the nucleated erythrocyte.
SUBST11TUTE SHEET (RULE 261 Also, fetal leukocytes have been reported to be present in maternal blood.
Leuko-cytes are one subpopulation of white blood cells found in the blood. There are three types of subsets of leukocytes (which also are referred to as polymorphnuclear leu-kocytes): neutrophils, basophils and eosinophils. All leukocytes have a distinctive morphology characterized by the nucleus and cellular granules.
Due to the very limited number of fetal cells in maternal blood concentration or en-richment of the maternal blood sample with respect to the fetal cells have been con-ducted by negative selection, i.e. removal of maternal cells. Enrichment of fetal cells by density gradient centrifugation or by removing maternal cells with an antibody to a cell surface antigen is described in for example US 5,858,649, US 5,731,156, US 5,766,843 and US 5,861,253.
Yet another method of removing maternal cells, in particular maternal erythrocytes, is by lysing, again optionally combined with immunologic methods for removing the maternal cells.
Another selection procedure is positive selection, for example by use of CD71 anti-bodies.
US 5,861,253 describes enrichment either before and/or after labelling of the fetal cells for further analysis.
It is however, a problem that due to the enrichment procedures some of the fetal cells may also be removed leading to even fewer fetal cells in the blood sample to be analysed.
In order to increase the number of fetal cells attempts of culturing the cells have been carried out in the prior art. There are a few publications describing successful methods for culturing fetal cells from peripheral blood of pregnant women. Lo et al, (Lancet 1994, 344, 264) cultured cells from five pregnant women carrying male fe-tuses. In two cases they examined samples before culturing with negative results. In all cases they ascertained cells by Fluorescence in situ hybridization (FISH) after culture. Very few details of the culture methodology are given, and the results have not been repeatable with the available information. In a study by Little et al, (Blood, SUBSTITUTE SHEET tRULE 261 273, R 1829) culture was used as part of their isolation method and male cells were found after various sorting/enrichment procedures. Also Jansen et al, (Prenatal Di-agnosis, 1999, 19, 323) developed a method for culturing cord blood cells in a model system for isolation of fetal nucleated red blood cells. However, none of the methods have shown a significant increase in fetal cells after culture.
Summary of the invention It is an object of the present invention to provide for a method for isolating fetal cells from maternal blood, wherein the blood sample has not been substantially enriched, such as by performing, on a sample of maternal blood from which at the most 50%
of the anucleated maternal cells thereof and/or at the most 50% of the nucleated maternal cells thereof have been removed, selective labelling of fetal cells in the maternal blood sample, identifying the selectively labelled fetal cells, and specifically isolating substantially only the selectively labelled fetal cells.
Thus, according to the invention a method is obtained whereby the risk of removing fetal cells from the maternal blood sample before analysing the sample has been greatly reduced.
Detailed description of the invention The present invention reveals a novel method of isolating fetal cells from maternal blood. The present method has proven to be optimised in relation to isolating meth-ods described in the prior art, and the present invention represents a method having beneficial properties technically and financially. In the light of the naturally occurring ratio between maternal cells and fetal cells the present invention presents a method wherein fetal cells are isolated from maternal blood without prior enrichment or con-centration of the sample, providing for a method of isolation by which the risk of los-ing fetal cells due to enrichment or concentration procedure has been reduced.
A major difference between maternal and fetal red blood cells is the latter having a nucleus, i.e. maternal red blood cells are anucleated. Furthermore, maternal blood contains three types of nucleated fetal cells, nucleated erythrocytes, syncytiotropho-blasts and leukocytes. It is an object of the present invention to provide for a method SUBSTITUTE SHEET (RULE 26) wherein the blood sample from which the fetal cells are isolated is substantially not enriched or concentrated prior to isolation by removing any of the maternal cells.
Accordingly, in order to reduce the risk of removing fetal cells in the preparation of maternal blood samples to be analysed it is an object of the present invention that at most 50 % of the maternal cells of the maternal blood sample have been removed or will be removed before or after the labelling of the fetal cells, thus that substan-tially no enrichment of the sample is carried out before identification of the cells. In a more preferred embodiment at most 20 % of the maternal cells have been removed, such as at the most 15% of the maternal cells, such as at most 10 % of the maternal cells, more preferred at most 5 % of the maternal cells, more preferably at most 2.5 % of the maternal cells, most preferred at most 1 % of the maternal cells.
According to the invention it is even more preferred that substantially none of the maternal cells have been removed from the sample.
Thus, it is encompassed by the present invention that at most 20 % of the maternal nucleated blood cells have been or will be removed and/or at most 20 % of the anu-cleated red blood cells have been or will be removed.
Even more preferred is a method wherein substantially none of the nucleated blood cells or anucleated red blood cells have been removed from the sample. Thereby the sample may be used as such directly after taking the maternal blood sample.
It is desirable to obtain as large a maternal blood sample as possible in order to in-crease the total number of fetal cells. However, due to proctical problems the sam-ple must be within certain limits. Accordingly, the size of the maternal blood sample is preferably in the range of 0,5 to 40 ml, such as in the range of 5 to 40 ml, such as from 10 to 30 ml.
Also, according to the invention it is preferred to dilute the sample before labelling or before identification of the fetal cells (to facilitate the identification of the fetal cells).
The sample may be diluted at least 1.5 times, such as twice, more preferred at least three times, such as five times by adding isotonic buffers, such as saline solutions, SUBSTITUTE SHE~~' tRULE 261 phosphate buffered saline solutions, PBS, and/or suitable growth media, such as basal media, and tissues growth media.
The selective labelling of the fetal cells may be carried out by any suitable method.
Introduction The present invention relates to a method for isolating fetal cells from maternal blood, in particular from maternal blood not having been subjected to concentration or enrichment.
In addition the invention relates to a method for culturing fetal cells.
Background The examination of fetal cells for early detection of fetal diseases and genetic ab-normalities is carried out in connection with many pregnancies, in particular when the maternal age is high (35 years or above) or where genetic diseases are known in the family. Fetal cells may be obtained by amniocentesis, the removal of amniotic fluid from the amniotic cavity within the amniotic sac or by chorion biopsy, where biopsies are taken from the placenta, a so-called invasive sampling.
During pregnancy a variety of cell types of fetal origin cross the placenta and circu-late within maternal peripheral blood. The feasability of using fetal cells in the ma-ternal circulation for diagnostic purposes has been hindered by the fact that fetal cells are present in maternal blood in only very limited numbers, reported numbers have been from 1:105 to 1:108 fetal cells per nucleated maternal cells. In addition most fetal cells cannot be distinguished from maternal cells on the basis of morphol-ogy alone, but rather must be identified based upon detection of fetal cell markers.
However, it would be advantageously to perform fetal diagnosis by a non-invasive procedure, such as a maternal blood sample.
One particular fetal cell type within maternal blood that has been demonstrated to be useful for detecting fetal DNA is the nucleated erythrocyte.
SUBST11TUTE SHEET (RULE 261 Also, fetal leukocytes have been reported to be present in maternal blood.
Leuko-cytes are one subpopulation of white blood cells found in the blood. There are three types of subsets of leukocytes (which also are referred to as polymorphnuclear leu-kocytes): neutrophils, basophils and eosinophils. All leukocytes have a distinctive morphology characterized by the nucleus and cellular granules.
Due to the very limited number of fetal cells in maternal blood concentration or en-richment of the maternal blood sample with respect to the fetal cells have been con-ducted by negative selection, i.e. removal of maternal cells. Enrichment of fetal cells by density gradient centrifugation or by removing maternal cells with an antibody to a cell surface antigen is described in for example US 5,858,649, US 5,731,156, US 5,766,843 and US 5,861,253.
Yet another method of removing maternal cells, in particular maternal erythrocytes, is by lysing, again optionally combined with immunologic methods for removing the maternal cells.
Another selection procedure is positive selection, for example by use of CD71 anti-bodies.
US 5,861,253 describes enrichment either before and/or after labelling of the fetal cells for further analysis.
It is however, a problem that due to the enrichment procedures some of the fetal cells may also be removed leading to even fewer fetal cells in the blood sample to be analysed.
In order to increase the number of fetal cells attempts of culturing the cells have been carried out in the prior art. There are a few publications describing successful methods for culturing fetal cells from peripheral blood of pregnant women. Lo et al, (Lancet 1994, 344, 264) cultured cells from five pregnant women carrying male fe-tuses. In two cases they examined samples before culturing with negative results. In all cases they ascertained cells by Fluorescence in situ hybridization (FISH) after culture. Very few details of the culture methodology are given, and the results have not been repeatable with the available information. In a study by Little et al, (Blood, SUBSTITUTE SHEET tRULE 261 273, R 1829) culture was used as part of their isolation method and male cells were found after various sorting/enrichment procedures. Also Jansen et al, (Prenatal Di-agnosis, 1999, 19, 323) developed a method for culturing cord blood cells in a model system for isolation of fetal nucleated red blood cells. However, none of the methods have shown a significant increase in fetal cells after culture.
Summary of the invention It is an object of the present invention to provide for a method for isolating fetal cells from maternal blood, wherein the blood sample has not been substantially enriched, such as by performing, on a sample of maternal blood from which at the most 50%
of the anucleated maternal cells thereof and/or at the most 50% of the nucleated maternal cells thereof have been removed, selective labelling of fetal cells in the maternal blood sample, identifying the selectively labelled fetal cells, and specifically isolating substantially only the selectively labelled fetal cells.
Thus, according to the invention a method is obtained whereby the risk of removing fetal cells from the maternal blood sample before analysing the sample has been greatly reduced.
Detailed description of the invention The present invention reveals a novel method of isolating fetal cells from maternal blood. The present method has proven to be optimised in relation to isolating meth-ods described in the prior art, and the present invention represents a method having beneficial properties technically and financially. In the light of the naturally occurring ratio between maternal cells and fetal cells the present invention presents a method wherein fetal cells are isolated from maternal blood without prior enrichment or con-centration of the sample, providing for a method of isolation by which the risk of los-ing fetal cells due to enrichment or concentration procedure has been reduced.
A major difference between maternal and fetal red blood cells is the latter having a nucleus, i.e. maternal red blood cells are anucleated. Furthermore, maternal blood contains three types of nucleated fetal cells, nucleated erythrocytes, syncytiotropho-blasts and leukocytes. It is an object of the present invention to provide for a method SUBSTITUTE SHEET (RULE 26) wherein the blood sample from which the fetal cells are isolated is substantially not enriched or concentrated prior to isolation by removing any of the maternal cells.
Accordingly, in order to reduce the risk of removing fetal cells in the preparation of maternal blood samples to be analysed it is an object of the present invention that at most 50 % of the maternal cells of the maternal blood sample have been removed or will be removed before or after the labelling of the fetal cells, thus that substan-tially no enrichment of the sample is carried out before identification of the cells. In a more preferred embodiment at most 20 % of the maternal cells have been removed, such as at the most 15% of the maternal cells, such as at most 10 % of the maternal cells, more preferred at most 5 % of the maternal cells, more preferably at most 2.5 % of the maternal cells, most preferred at most 1 % of the maternal cells.
According to the invention it is even more preferred that substantially none of the maternal cells have been removed from the sample.
Thus, it is encompassed by the present invention that at most 20 % of the maternal nucleated blood cells have been or will be removed and/or at most 20 % of the anu-cleated red blood cells have been or will be removed.
Even more preferred is a method wherein substantially none of the nucleated blood cells or anucleated red blood cells have been removed from the sample. Thereby the sample may be used as such directly after taking the maternal blood sample.
It is desirable to obtain as large a maternal blood sample as possible in order to in-crease the total number of fetal cells. However, due to proctical problems the sam-ple must be within certain limits. Accordingly, the size of the maternal blood sample is preferably in the range of 0,5 to 40 ml, such as in the range of 5 to 40 ml, such as from 10 to 30 ml.
Also, according to the invention it is preferred to dilute the sample before labelling or before identification of the fetal cells (to facilitate the identification of the fetal cells).
The sample may be diluted at least 1.5 times, such as twice, more preferred at least three times, such as five times by adding isotonic buffers, such as saline solutions, SUBSTITUTE SHE~~' tRULE 261 phosphate buffered saline solutions, PBS, and/or suitable growth media, such as basal media, and tissues growth media.
The selective labelling of the fetal cells may be carried out by any suitable method.
5 Fetal cells may be distinguished from maternal cells by the specific recognition of a fetal cell antigen or they may be distinguished by staining with a labelled antibody to a protein selectively produced by fetal cells or they may be distinguished from ma-ternal cells by the specific recognition of DNA or RNA encoding a protein selectively or substantially selectively produced by fetal cells.
Accordingly, it is an object of the present invention to provide for the selective label-ling of fetal blood cells in the maternal blood sample based on hybridisation of a probe to m-RNA selectively expressed by fetal cells.
Preferably, fetal-cell-specific RNA sequences are used as fetal cell markers.
Such RNA is generally messenger RNA (mRNA). The presence of such RNA indicates that the gene for the fetal protein is being transcribed and expressed. (The probes used to identify fetal cells in a sample containing fetal and maternal cells include nucleic acid molecules, which comprise the nucleotide sequence complementary to the nucleotide sequence of the RNA molecule encoding a specific protein. Fetal cells contain distinct mRNAs or RNA species that do not occur in other cell types.
The detection of these RNAs, whether as mRNA can serve to identify cells, or even subcellular fractions of cells fetal or embryonic in origin). According to the present invention the m-RNA to be detected may be coding for a protein selected from the group consisting of embryonic hemoglobin, such as s and zeta globin chains, and fetal hemoglobin, such as gamma and alpha globin chains.
Further, according to the present invention DNA probes (oligos) for the hybridisation are directed against embryonic cell RNA, such as for E and zeta globin chains, and for fetal hemoglobin, such as for gamma and alpha globin chains. A DNA probe may be synthesised as an oligodeoxynucleotide using a commercial synthesiser.
Probes may be comprised of the natural nucleotide bases or known analogues of the natu-ral nucleotide bases.
SU8ST11TUTE SHEET (RULE 26) Yet further to the invention the hybridisation probe for the DNA or RNA
discussed above is selected from peptide nucleic acid (PNA) probes and other synthetic mole-cules capable of Watson Crick-base pairing with the fetal m-RNA.
In one embodiment of the invention the probe as discussed above, such as a syn-thetic DNA probe, is directly labelled, by having fluorochromes covalently attached thereto. The binding of such probes to the cell may be observed under a microscope as a bright fluorescence or may be detected by a fluorimetric apparatus.
Instead of direct labelling or in addition to the direct labelling in another embodiment the probes are indirectly labelled with biotin or enzymes for example, such as alka-line phosphatase.
By using a combination of labelling methods it is possible to enhance the signals from the fetal cells, thereby facilitating the identification thereof.
Certain RNA populations are present in high abundance and other fetal or embry-onic-specific RNAs are present in low abundance. Several RNA species occur simultanously in fetal cells as opposed to maternal cells. This provides for yet an-other method of enhancing the distinction between fetal cells and non-fetal cells by the detection of multiple RNA species. Two or more RNA species may be detected using one or more probes for a first RNA sequence and one or more probes for a second RNA sequence. The probes for the first sequence are labelled to provide a first signal, such as a greenish fluorescence, and the probes for the second se-quence are labelled to provide a signal that is different from the first signal, such as a reddish fluorescence. When the combination of both signals are detected in a sin-gle cell, which in this case would be an orange fluorescence, then both RNAs are found and thus a fetal cell has been detected.
According to another method of the invention the selective labelling is based on an antigen-antibody reaction with a protein selectively produced by fetal cells.
Such a protein may be selected from the group consisting of embryonic hemoglobin, such as s and zeta globin chains, and fetal hemoglobin, such as gamma and alpha globin chains.
suesTnvTE sH~ rRUI~ 2s~
Accordingly, it is an object of the present invention to provide for the selective label-ling of fetal blood cells in the maternal blood sample based on hybridisation of a probe to m-RNA selectively expressed by fetal cells.
Preferably, fetal-cell-specific RNA sequences are used as fetal cell markers.
Such RNA is generally messenger RNA (mRNA). The presence of such RNA indicates that the gene for the fetal protein is being transcribed and expressed. (The probes used to identify fetal cells in a sample containing fetal and maternal cells include nucleic acid molecules, which comprise the nucleotide sequence complementary to the nucleotide sequence of the RNA molecule encoding a specific protein. Fetal cells contain distinct mRNAs or RNA species that do not occur in other cell types.
The detection of these RNAs, whether as mRNA can serve to identify cells, or even subcellular fractions of cells fetal or embryonic in origin). According to the present invention the m-RNA to be detected may be coding for a protein selected from the group consisting of embryonic hemoglobin, such as s and zeta globin chains, and fetal hemoglobin, such as gamma and alpha globin chains.
Further, according to the present invention DNA probes (oligos) for the hybridisation are directed against embryonic cell RNA, such as for E and zeta globin chains, and for fetal hemoglobin, such as for gamma and alpha globin chains. A DNA probe may be synthesised as an oligodeoxynucleotide using a commercial synthesiser.
Probes may be comprised of the natural nucleotide bases or known analogues of the natu-ral nucleotide bases.
SU8ST11TUTE SHEET (RULE 26) Yet further to the invention the hybridisation probe for the DNA or RNA
discussed above is selected from peptide nucleic acid (PNA) probes and other synthetic mole-cules capable of Watson Crick-base pairing with the fetal m-RNA.
In one embodiment of the invention the probe as discussed above, such as a syn-thetic DNA probe, is directly labelled, by having fluorochromes covalently attached thereto. The binding of such probes to the cell may be observed under a microscope as a bright fluorescence or may be detected by a fluorimetric apparatus.
Instead of direct labelling or in addition to the direct labelling in another embodiment the probes are indirectly labelled with biotin or enzymes for example, such as alka-line phosphatase.
By using a combination of labelling methods it is possible to enhance the signals from the fetal cells, thereby facilitating the identification thereof.
Certain RNA populations are present in high abundance and other fetal or embry-onic-specific RNAs are present in low abundance. Several RNA species occur simultanously in fetal cells as opposed to maternal cells. This provides for yet an-other method of enhancing the distinction between fetal cells and non-fetal cells by the detection of multiple RNA species. Two or more RNA species may be detected using one or more probes for a first RNA sequence and one or more probes for a second RNA sequence. The probes for the first sequence are labelled to provide a first signal, such as a greenish fluorescence, and the probes for the second se-quence are labelled to provide a signal that is different from the first signal, such as a reddish fluorescence. When the combination of both signals are detected in a sin-gle cell, which in this case would be an orange fluorescence, then both RNAs are found and thus a fetal cell has been detected.
According to another method of the invention the selective labelling is based on an antigen-antibody reaction with a protein selectively produced by fetal cells.
Such a protein may be selected from the group consisting of embryonic hemoglobin, such as s and zeta globin chains, and fetal hemoglobin, such as gamma and alpha globin chains.
suesTnvTE sH~ rRUI~ 2s~
In particular the labelling may be carried out by the use of an antibody selected from antibodies against various types of normal globin chains in human hemoglobin, for example anti epsilon (E) antibodies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibodies, monoclonal biotin and fluorochrome labelled antibodies, and monoclonal fluorochrome labelled antibodies, anti zeta (~) antibod-ies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibod-ies, monoclonal fluorochrome labeled antibodies, and polyclonal fluorochrome la-beled antibodies, anti gamma (y) antibodies, such as polyclonal (sheep) antibodies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibodies, monoclonal fluorochrome labeled antibodies, and polyclonal fluorochrome labeled antibodies, anti alpha (a) antibodies, and anti beta (~i) antibodies.
The fluorochrome is selected to be excited in the wave-length area of the detection means, and furthermore in suitable combination with an optional second labelling.
In particular the fluorochromes may be selected from FITC (fluorescein-isofluocyanate) or TRITC (Rhodanine Tetramethyl- isofluocyanate) having excitation at 495 nm and 555 nm, respectively.
In a preferred embodiment of the present invention the labelling is carried out using anti epsilon (s) monoclonal antibodies or anti zeta (~) monoclonal antibodies, more preferably anti epsilon (E) unlabelled monoclonal antibodies or anti zeta (~) unla-belted monoclonal antibodies, or anti epsilon (s) monoclonal biotin labelled antibod-ies or anti zeta (~) monoclonal biotin labelled antibodies.
The unlabelled antibodies are used as known in the art, by using a second labelling step with eg. second antibodies against the unlabelled antibody, said antibody being labelled as discussed above, such as fluorochrome labelled. By this two-step it may be possible to enhance the signals from the fetal cells.
In another preferred embodiment of the invention the labelling is performed using anti gamma (y) fluorochrome labeled antibodies, such as FITC labelled antibodies.
In order to enhance the probability and selectivity of identifying the fetal cells or the background of maternal cells by the labelling two or more selective labellings may be performed. The combination of two or more labellings may be a combination of SUBST>TUTE SHEET !RULE 261 any of the labellings used for single labelling as well. Accordingly, the combined labelling may be carried out by the use of two or more different hybridisation probes, such as a combination of a DNA probe and a PNA probe for hybridisation with the same fetal RNA or more preferred with different RNAs. Also, two or more different DNA probes (or PNA probes) may be used for hybridisation with different fetal RNAs.
The enhanced selective labelling may also by carried out by the use of two or more antibodies directed against the same protein or different proteins. In this embodi-ment the labelling with two or more labels may be carried out simultaneously.
In another embodiment a combination of an immunological labelling and a hybridi-sation labelling may be employed according to the present invention. In this em-bodiment the labelling is normally carried out sequentially by a first immunological labelling step, then identification of the labelled cells, and then a second step of hy-bridisation labelling for verification of the identification of the cells labelled by the first step. It is preferred in the first step to use antibodies against gamma globin and in the second step to use hybridisation for epsilon and/or zeta globin and/or gamma mRNA to verify the fetal cells identified.
In yet another embodiment the verification may be conducted by a second step of staining the cell nucleus since the maternal cells probable to be detected will be anucleated maternal cells, i.e. maternal erythrocytes. Thus by verifying that identi-fled cells contain a nucleus it is ensured that fetal cells have been identified. In par-ticular the nucleus staining is selected from 4,6-diamidino-2-phenylindole (DAPI) or propidium-iodide (PI).
An important feature of the present invention is the identification of the labelled fetal cells without the sample being enriched or concentrated with respect to the fetal cells in order to avoid loss of fetal cells. Accordingly, the method according to the present invention comprises identification of the selectively labelled fetal cells.
In one embodiment the identification is performed by spreading the blood sample on a solid surface and detecting the labelled cells on the surface. The detection may be carried out by any suitable means in accordance with the labelling method in ques-SU8ST1TUTE SHEET tRULE 261 tion. The choice of solid support surface may depend upon the procedure for visu alisation of the cells. Some materials are not uniform and therefore shrinking and swelling during in situ hybridisation procedures will not be uniform leading to inaccu-racy in the identification procedure. Other autofluoresce support materials will inter-s fere with the determination of low level fluorescence. Support materials according to the invention preferably comprise glass, nylon, nitrocellulose and Scotch tape, and any suitable membranes, such as filtermembranes. Preferably, the collected sam-ples are spread on a support surface in a monolayer for the cells not to overlap one another. Also, the in situ hybridization process according to the invention may car-ried out on fetal cells attached to a solid support.
Various antibodies have been used to discriminate between maternal and fetal cells as discussed above. In one embodiment the antibodies may be coupled to numer-ous solid surfaces or supports/substrates, such as containers, columns, wells, beads, or particles by physical or chemical bonding. Alternatively, the antibodies may be coupled to a compound which facilitates the separation step. For example antibodies may be labelled with fluorescent markers and cells to which these la-belted antibodies bind may thereby be separated with a cell sorter according to known procedures.
The nucleic acid of the fetal cells can be amplified prior to detection using a known amplification technique, such as the polymerise chain reaction (PCR). Primers for PCR amplification are chosen to specifically amplify a DNA of interest in the fetal DNA.
Due to the large amount of cells to be examined to find the small amount of fetal cells in the blood sample an important factor for the detection equipment is the rate of cells identified per unit of time. For example very fast scanning microscopes may be used for the identification. Also, laser scanners could be used. Preferably the laser scanner is equipped with at least two lasers emitting light with different wave-length capable to excite the various labels on the cells or in one laser emitting sev-eral wavelengths.
SUBST11TUTE SHEET iRULE 281 Preferably, during or after identification of the fetal cells the position of detected la-belled cells on the surface is recorded. This provides for the later collection of the detected cells from the position which has been recorded. The position of the de-tected labelled cells on the supporting surface may be recorded by use of a scanner 5 provided with detectors registering the light emitted from the labelled cells, such photo-multipliers, CCDs, or the like detectors. Thereby it is possible to identify and specifically isolate substantially only the selectively labelled fetal cells.
In a preferred embodiment the scanner is arranged for detecting selectively labelled 10 fetal cells, and when detecting a fetal cell, carrying out a verification step by switch-ing to another wavelength to verify presence of for example staining of the nucleus.
It is of importance for the use of the method that a fast scanning system is used, for example a scanner capable of scanning in the range of from 0.1 m/sec to 10 m/sec or faster, such as appr. 1 m/sec.
The cells collected according to any of the procedures may be subjected to further identification and/or investigation, such as microscopic andlor molecular identifica-tion and/or investigation. The cells may be subjected to investigations of analysing the presence of genetic diseases, for example. The nucleic acid of fetal cells may be analysed for diagnostic or other purposes. For instance the presence or absence of a gene or a gene mutation may indicate the presence of diseases, such as cystic fibrosis. The nucleic acid may additionally be analysed for X or Y
specificity. Thus, the presence of a Y chromosome encoded genes or gene products is a qualitative distinguishing feature of the cells of a male fetus.
Verification of the selective identification of fetal cells may be carried out by several methods. In a model system the method may be performed on maternal blood sam-ples from pregnant women carrying a male fetus. The cells isolated may then be analysed for the presence of a Y chromosome, indicative of cells being from the male fetus.
Another verification method, which is usable independent of the sex of the fetus, is verification by use of identification of small tandem repeats (STR) or variable num-ber tandem repeats (VNTR) to detect genetic input from the father, thereby verifying fetal cells, as the only cells in the sample comprising input from the father.
SU8ST1TUTE SHEET (RULE 261 As may be understood from the above the present method may be carried out for the isolation of any kind of rare event cells in a blood sample, and is particular inter-esting when used for rare event cells being present in very low concentrations, such as those for the fetal cells in maternal blood. This may for example also be true for some cancer forms.
Further, according to the present invention a method for multiplying fetal blood cells, preferably fetal red blood cells, in a cell culture comprising fetal blood cells and other cells, in particular maternal blood cells may be employed. The cultivation may be carried out on any sample comprising fetal blood cells, such as umbilical cord sam-ples from aborted fetuses, or maternal blood samples.
The multiplication of the fetal cells is desirable to achieve due to the use of the pres-ent invention. The method according to the invention comprises performing the cell culturing in a culture medium containing growth factors necessary for the multiplica-tion of fetal cells.
The multiplication may be conducted by any suitable method as known to the per-son skilled in the art.
The method of culturing fetal cells may be combined with the method of selectively isolating fetal cells in any suitable manner. Accordingly, a maternal blood sample may be subjected to cultivation of fetal cells before subjecting the sample to label-ling, identification and isolation of the fetal cells. Thereby the starting concentrations of fetal cells in the maternal blood sample are increased without removing any cells originating from the mother. The culture method may also be used in connection with analysis of maternal blood samples that have been pretreated in order to re-move some of the maternal cells.
When the labelling and identification procedures allow viable cells to be selected the culture method may be conducted on fetal cells having been identified and isolated according to the isolation method described above, in order to increase the amount of fetal cells for further analysis.
SUBSTITUTE SHEET (RULE 261 After cultivation the fetal cells may be harvested by any suitable method. In case the colonies obtained are harvested collectively, there will be a very high number of cells of which only some will be from the fetus. Contrary to this, colonies may be harvested individually to increase the rate of fetal cells in the harvested material.
Also, the invention relates to a method of diagnosing a disease in a fetus comprising obtaining a blood sample from the woman pregnant with said fetus, whereby at most 50 % of the maternal nucleated cells have been removed and/or at most 50 % of the maternal anucleated cells have been removed from said blood sample, selectively labelling the fetal cells in the maternal blood sample, identifying the selectively la-belted fetal cells, specifically labelling with at least one disease marker the identified fetal cells for diseases, and identifying specifically labelled cells.
The selective labelling and identification of the cells are carried out as described above. The specific labelling with at least one disease marker refers to the labelling of the identified cells with a marker, such as a probe, to a gene or a gene mutation specific for the genetic disease or a chromosome abnormality to be diagnosed.
In a preferred embodiment wherein the fetal cells are isolated before specifically labelling the fetal cells.
Furthermore, the present invention relates to the use of the present method for di-agnosing a disease of the fetus, such as a genetic disease. The genetic disease may be any genetic disease or a chromosome abnormality, such as cystic fibrosis, hemophilia, muscular dystrophy, Down' syndrome, Klinefelter, or Turner' syndrome.
The invention is further exemplified by the following non-limiting examples.
Examples Example 1 Fixation of peripheral venous blood cells before mounting on slides.
The blood is fixed according to table I below and mounted on slides as described.
SUBSTinJTE SHEET (RULE 267 Table I
Step Procedure: Fixation and slide preparation.Time Tempera-ture 1 100 I blood. Ad 100 I Hank's Ca++ and R.T.
M ++ free or PBS
2 Ad 200 I 4% araformaldeh de in PBS Vortex1 hr 37 C
3 Ad 3 ml PBS +,- 3%BSA R.T.
4 S in at 1500 r m 5 min. R.T.
Permeate cells with 1 ml methanol/acetone1 hr- 4 ~C
(1+1, - o.n*
20C Vortex 6 Ad 3 ml cold PBS 4 C
7 S in at 1500 r m 5 min R.T.
8 Wash cells in cold PBS +,- 3%BSA . 4 C.
9 S in at 1500 r m 5 min R.T.
Resus end cells in PBS a rox. 100 I +,- R.T.
3% BSA
11 Pre are slides. Smears on of -L-I sine R.T.
coated slides.
12 Store slides sealed individually in plasticbagsl -80 ~C
* o.n. = over night.
5 The slides prepared are stained with antibodies against globin chains and embry-onic globin chains as described below in table II.
Table II
Step Procedure: Antibody staining of slides Time Tempera-ture 1 Wash slides in PBS 2 x 5 R.T.
min 2 Wask slides in 4xSSC 10 min R.T.
3 Block in 4xSSC/1%BSA/0,5% Boehringer blocking10 min R.T.
reagent Buffer A
4 Inkubate with primary (anti-globin chain 30 min R.T.
antibody, 2-3 humid p.g/slide) diluted in buffer A. atm.
5 Wash in 4xSSC/0,5% Tween20 2 x 5 R.T.
min 6 Inkubate with biotinylated goat anti-mouse30 min R.T.
diluted in buffer humid A, atm.
7 Wash in 4xSSC/0,5% Tween 20 2 x 5 R.T.
min 8 Inkubate with fluorochrome conjugated 30 min R.T.
avidin/streptavidin humid diluted in buffer A atm.
9 Wash in 4xSSC/0,5%Tween 20 2 x 5 R.T.
min 10 Wash in 2xSSC 5 min R.T.
11 Mount in Vectashield with counterstain R.T.
added DAPI or PI
12 Store slides in darkness 4 C
10 Vectashield is a trademark to Vector Laboratories, USA.
SUHST1TUTE SHEET (RULE 26) After staining the slides may be stored for later identification of the fetal cells. The identification may be carried out in a laser scanner.
Example 2 Mounting on slides before fixation.
Pheripheral venous blood is obtained from the pregnant woman.
Slides are prepared by smearing the blood on poly-L-lysine coated slides, whereaf-ter the slides are stored individually in plastic bags at -20 °C. The fixation is carried out as described in table III.
Tahle III
..
Ste Procedure: Fixation. Time Tem erature 1 Fix cells in 2% araformaldeh de 10 min RT
in PBS.
2 Permeabilize cells methanol/acetone 10 min -20 C
1:1 Antibody staining and identification is as described in example 1. The cell morphol-ogy is maintained more consistently when mounting on slides before fixation is car-ried out.
Example 3 Verification of fetal cells by identifying the Y chromosomes Fetal cells were diagnosed by the Y chromosome FISH analysis by the following procedure:
Maternal whole blood is smeared onto a slide, and fixed 2 minutes in paraformalde-hyde (2 %) at room temperature. The cells are permeabilised 10 minutes in acetone at -20 °C, and then washed 3 minutes in PBS-buffer at room temperature.
The slides are dehydrated in 62%, 96% and 99% alcohol at room temperature, and air-dried. A DNA probe 'pBAM-X' for the X-chromosome labelled with digoxigenin and a DNA probe 'ph-y 2,1' for the Y-chromosome labelled with biotin are used. The slide is placed on a heating plate at 37 °C, and the probe is added to the slide and a SUBSTfT'UTE SHEET (RULE 261 cover glass placed on top of it and sealed with glue. The slide is placed immediately on a heating plate at 83,5 °C in 7 minutes, and hybridisation is conducted over night at 42 °C in moistened air.
5 After hybridisation the glue is removed and the slide is washed in 2xSSC
until the cover glass releases, the in 0.4xSSC/0.3% NP-40 in 2 minutes at 73 °C.
Then in 2xSSC/0.1 % NP-40 in 1 minute at room temperature, and then rinsed in 2xSSC.
The slide is incubated 20 minutes at 37 °C with fluorescein-labelled avidin/rhodamin 10 labelled anti-digoxigenin, and then washed 5 minutes in 4xSSC/0.1 % tween 20, rinsed in 2xSSC and air dryed.
The slide is then mounted in Vectashield with counterstain added (DAPI or PI).
The fluorochrome is selected to be excited in the wave-length area of the detection means, and furthermore in suitable combination with an optional second labelling.
In particular the fluorochromes may be selected from FITC (fluorescein-isofluocyanate) or TRITC (Rhodanine Tetramethyl- isofluocyanate) having excitation at 495 nm and 555 nm, respectively.
In a preferred embodiment of the present invention the labelling is carried out using anti epsilon (s) monoclonal antibodies or anti zeta (~) monoclonal antibodies, more preferably anti epsilon (E) unlabelled monoclonal antibodies or anti zeta (~) unla-belted monoclonal antibodies, or anti epsilon (s) monoclonal biotin labelled antibod-ies or anti zeta (~) monoclonal biotin labelled antibodies.
The unlabelled antibodies are used as known in the art, by using a second labelling step with eg. second antibodies against the unlabelled antibody, said antibody being labelled as discussed above, such as fluorochrome labelled. By this two-step it may be possible to enhance the signals from the fetal cells.
In another preferred embodiment of the invention the labelling is performed using anti gamma (y) fluorochrome labeled antibodies, such as FITC labelled antibodies.
In order to enhance the probability and selectivity of identifying the fetal cells or the background of maternal cells by the labelling two or more selective labellings may be performed. The combination of two or more labellings may be a combination of SUBST>TUTE SHEET !RULE 261 any of the labellings used for single labelling as well. Accordingly, the combined labelling may be carried out by the use of two or more different hybridisation probes, such as a combination of a DNA probe and a PNA probe for hybridisation with the same fetal RNA or more preferred with different RNAs. Also, two or more different DNA probes (or PNA probes) may be used for hybridisation with different fetal RNAs.
The enhanced selective labelling may also by carried out by the use of two or more antibodies directed against the same protein or different proteins. In this embodi-ment the labelling with two or more labels may be carried out simultaneously.
In another embodiment a combination of an immunological labelling and a hybridi-sation labelling may be employed according to the present invention. In this em-bodiment the labelling is normally carried out sequentially by a first immunological labelling step, then identification of the labelled cells, and then a second step of hy-bridisation labelling for verification of the identification of the cells labelled by the first step. It is preferred in the first step to use antibodies against gamma globin and in the second step to use hybridisation for epsilon and/or zeta globin and/or gamma mRNA to verify the fetal cells identified.
In yet another embodiment the verification may be conducted by a second step of staining the cell nucleus since the maternal cells probable to be detected will be anucleated maternal cells, i.e. maternal erythrocytes. Thus by verifying that identi-fled cells contain a nucleus it is ensured that fetal cells have been identified. In par-ticular the nucleus staining is selected from 4,6-diamidino-2-phenylindole (DAPI) or propidium-iodide (PI).
An important feature of the present invention is the identification of the labelled fetal cells without the sample being enriched or concentrated with respect to the fetal cells in order to avoid loss of fetal cells. Accordingly, the method according to the present invention comprises identification of the selectively labelled fetal cells.
In one embodiment the identification is performed by spreading the blood sample on a solid surface and detecting the labelled cells on the surface. The detection may be carried out by any suitable means in accordance with the labelling method in ques-SU8ST1TUTE SHEET tRULE 261 tion. The choice of solid support surface may depend upon the procedure for visu alisation of the cells. Some materials are not uniform and therefore shrinking and swelling during in situ hybridisation procedures will not be uniform leading to inaccu-racy in the identification procedure. Other autofluoresce support materials will inter-s fere with the determination of low level fluorescence. Support materials according to the invention preferably comprise glass, nylon, nitrocellulose and Scotch tape, and any suitable membranes, such as filtermembranes. Preferably, the collected sam-ples are spread on a support surface in a monolayer for the cells not to overlap one another. Also, the in situ hybridization process according to the invention may car-ried out on fetal cells attached to a solid support.
Various antibodies have been used to discriminate between maternal and fetal cells as discussed above. In one embodiment the antibodies may be coupled to numer-ous solid surfaces or supports/substrates, such as containers, columns, wells, beads, or particles by physical or chemical bonding. Alternatively, the antibodies may be coupled to a compound which facilitates the separation step. For example antibodies may be labelled with fluorescent markers and cells to which these la-belted antibodies bind may thereby be separated with a cell sorter according to known procedures.
The nucleic acid of the fetal cells can be amplified prior to detection using a known amplification technique, such as the polymerise chain reaction (PCR). Primers for PCR amplification are chosen to specifically amplify a DNA of interest in the fetal DNA.
Due to the large amount of cells to be examined to find the small amount of fetal cells in the blood sample an important factor for the detection equipment is the rate of cells identified per unit of time. For example very fast scanning microscopes may be used for the identification. Also, laser scanners could be used. Preferably the laser scanner is equipped with at least two lasers emitting light with different wave-length capable to excite the various labels on the cells or in one laser emitting sev-eral wavelengths.
SUBST11TUTE SHEET iRULE 281 Preferably, during or after identification of the fetal cells the position of detected la-belled cells on the surface is recorded. This provides for the later collection of the detected cells from the position which has been recorded. The position of the de-tected labelled cells on the supporting surface may be recorded by use of a scanner 5 provided with detectors registering the light emitted from the labelled cells, such photo-multipliers, CCDs, or the like detectors. Thereby it is possible to identify and specifically isolate substantially only the selectively labelled fetal cells.
In a preferred embodiment the scanner is arranged for detecting selectively labelled 10 fetal cells, and when detecting a fetal cell, carrying out a verification step by switch-ing to another wavelength to verify presence of for example staining of the nucleus.
It is of importance for the use of the method that a fast scanning system is used, for example a scanner capable of scanning in the range of from 0.1 m/sec to 10 m/sec or faster, such as appr. 1 m/sec.
The cells collected according to any of the procedures may be subjected to further identification and/or investigation, such as microscopic andlor molecular identifica-tion and/or investigation. The cells may be subjected to investigations of analysing the presence of genetic diseases, for example. The nucleic acid of fetal cells may be analysed for diagnostic or other purposes. For instance the presence or absence of a gene or a gene mutation may indicate the presence of diseases, such as cystic fibrosis. The nucleic acid may additionally be analysed for X or Y
specificity. Thus, the presence of a Y chromosome encoded genes or gene products is a qualitative distinguishing feature of the cells of a male fetus.
Verification of the selective identification of fetal cells may be carried out by several methods. In a model system the method may be performed on maternal blood sam-ples from pregnant women carrying a male fetus. The cells isolated may then be analysed for the presence of a Y chromosome, indicative of cells being from the male fetus.
Another verification method, which is usable independent of the sex of the fetus, is verification by use of identification of small tandem repeats (STR) or variable num-ber tandem repeats (VNTR) to detect genetic input from the father, thereby verifying fetal cells, as the only cells in the sample comprising input from the father.
SU8ST1TUTE SHEET (RULE 261 As may be understood from the above the present method may be carried out for the isolation of any kind of rare event cells in a blood sample, and is particular inter-esting when used for rare event cells being present in very low concentrations, such as those for the fetal cells in maternal blood. This may for example also be true for some cancer forms.
Further, according to the present invention a method for multiplying fetal blood cells, preferably fetal red blood cells, in a cell culture comprising fetal blood cells and other cells, in particular maternal blood cells may be employed. The cultivation may be carried out on any sample comprising fetal blood cells, such as umbilical cord sam-ples from aborted fetuses, or maternal blood samples.
The multiplication of the fetal cells is desirable to achieve due to the use of the pres-ent invention. The method according to the invention comprises performing the cell culturing in a culture medium containing growth factors necessary for the multiplica-tion of fetal cells.
The multiplication may be conducted by any suitable method as known to the per-son skilled in the art.
The method of culturing fetal cells may be combined with the method of selectively isolating fetal cells in any suitable manner. Accordingly, a maternal blood sample may be subjected to cultivation of fetal cells before subjecting the sample to label-ling, identification and isolation of the fetal cells. Thereby the starting concentrations of fetal cells in the maternal blood sample are increased without removing any cells originating from the mother. The culture method may also be used in connection with analysis of maternal blood samples that have been pretreated in order to re-move some of the maternal cells.
When the labelling and identification procedures allow viable cells to be selected the culture method may be conducted on fetal cells having been identified and isolated according to the isolation method described above, in order to increase the amount of fetal cells for further analysis.
SUBSTITUTE SHEET (RULE 261 After cultivation the fetal cells may be harvested by any suitable method. In case the colonies obtained are harvested collectively, there will be a very high number of cells of which only some will be from the fetus. Contrary to this, colonies may be harvested individually to increase the rate of fetal cells in the harvested material.
Also, the invention relates to a method of diagnosing a disease in a fetus comprising obtaining a blood sample from the woman pregnant with said fetus, whereby at most 50 % of the maternal nucleated cells have been removed and/or at most 50 % of the maternal anucleated cells have been removed from said blood sample, selectively labelling the fetal cells in the maternal blood sample, identifying the selectively la-belted fetal cells, specifically labelling with at least one disease marker the identified fetal cells for diseases, and identifying specifically labelled cells.
The selective labelling and identification of the cells are carried out as described above. The specific labelling with at least one disease marker refers to the labelling of the identified cells with a marker, such as a probe, to a gene or a gene mutation specific for the genetic disease or a chromosome abnormality to be diagnosed.
In a preferred embodiment wherein the fetal cells are isolated before specifically labelling the fetal cells.
Furthermore, the present invention relates to the use of the present method for di-agnosing a disease of the fetus, such as a genetic disease. The genetic disease may be any genetic disease or a chromosome abnormality, such as cystic fibrosis, hemophilia, muscular dystrophy, Down' syndrome, Klinefelter, or Turner' syndrome.
The invention is further exemplified by the following non-limiting examples.
Examples Example 1 Fixation of peripheral venous blood cells before mounting on slides.
The blood is fixed according to table I below and mounted on slides as described.
SUBSTinJTE SHEET (RULE 267 Table I
Step Procedure: Fixation and slide preparation.Time Tempera-ture 1 100 I blood. Ad 100 I Hank's Ca++ and R.T.
M ++ free or PBS
2 Ad 200 I 4% araformaldeh de in PBS Vortex1 hr 37 C
3 Ad 3 ml PBS +,- 3%BSA R.T.
4 S in at 1500 r m 5 min. R.T.
Permeate cells with 1 ml methanol/acetone1 hr- 4 ~C
(1+1, - o.n*
20C Vortex 6 Ad 3 ml cold PBS 4 C
7 S in at 1500 r m 5 min R.T.
8 Wash cells in cold PBS +,- 3%BSA . 4 C.
9 S in at 1500 r m 5 min R.T.
Resus end cells in PBS a rox. 100 I +,- R.T.
3% BSA
11 Pre are slides. Smears on of -L-I sine R.T.
coated slides.
12 Store slides sealed individually in plasticbagsl -80 ~C
* o.n. = over night.
5 The slides prepared are stained with antibodies against globin chains and embry-onic globin chains as described below in table II.
Table II
Step Procedure: Antibody staining of slides Time Tempera-ture 1 Wash slides in PBS 2 x 5 R.T.
min 2 Wask slides in 4xSSC 10 min R.T.
3 Block in 4xSSC/1%BSA/0,5% Boehringer blocking10 min R.T.
reagent Buffer A
4 Inkubate with primary (anti-globin chain 30 min R.T.
antibody, 2-3 humid p.g/slide) diluted in buffer A. atm.
5 Wash in 4xSSC/0,5% Tween20 2 x 5 R.T.
min 6 Inkubate with biotinylated goat anti-mouse30 min R.T.
diluted in buffer humid A, atm.
7 Wash in 4xSSC/0,5% Tween 20 2 x 5 R.T.
min 8 Inkubate with fluorochrome conjugated 30 min R.T.
avidin/streptavidin humid diluted in buffer A atm.
9 Wash in 4xSSC/0,5%Tween 20 2 x 5 R.T.
min 10 Wash in 2xSSC 5 min R.T.
11 Mount in Vectashield with counterstain R.T.
added DAPI or PI
12 Store slides in darkness 4 C
10 Vectashield is a trademark to Vector Laboratories, USA.
SUHST1TUTE SHEET (RULE 26) After staining the slides may be stored for later identification of the fetal cells. The identification may be carried out in a laser scanner.
Example 2 Mounting on slides before fixation.
Pheripheral venous blood is obtained from the pregnant woman.
Slides are prepared by smearing the blood on poly-L-lysine coated slides, whereaf-ter the slides are stored individually in plastic bags at -20 °C. The fixation is carried out as described in table III.
Tahle III
..
Ste Procedure: Fixation. Time Tem erature 1 Fix cells in 2% araformaldeh de 10 min RT
in PBS.
2 Permeabilize cells methanol/acetone 10 min -20 C
1:1 Antibody staining and identification is as described in example 1. The cell morphol-ogy is maintained more consistently when mounting on slides before fixation is car-ried out.
Example 3 Verification of fetal cells by identifying the Y chromosomes Fetal cells were diagnosed by the Y chromosome FISH analysis by the following procedure:
Maternal whole blood is smeared onto a slide, and fixed 2 minutes in paraformalde-hyde (2 %) at room temperature. The cells are permeabilised 10 minutes in acetone at -20 °C, and then washed 3 minutes in PBS-buffer at room temperature.
The slides are dehydrated in 62%, 96% and 99% alcohol at room temperature, and air-dried. A DNA probe 'pBAM-X' for the X-chromosome labelled with digoxigenin and a DNA probe 'ph-y 2,1' for the Y-chromosome labelled with biotin are used. The slide is placed on a heating plate at 37 °C, and the probe is added to the slide and a SUBSTfT'UTE SHEET (RULE 261 cover glass placed on top of it and sealed with glue. The slide is placed immediately on a heating plate at 83,5 °C in 7 minutes, and hybridisation is conducted over night at 42 °C in moistened air.
5 After hybridisation the glue is removed and the slide is washed in 2xSSC
until the cover glass releases, the in 0.4xSSC/0.3% NP-40 in 2 minutes at 73 °C.
Then in 2xSSC/0.1 % NP-40 in 1 minute at room temperature, and then rinsed in 2xSSC.
The slide is incubated 20 minutes at 37 °C with fluorescein-labelled avidin/rhodamin 10 labelled anti-digoxigenin, and then washed 5 minutes in 4xSSC/0.1 % tween 20, rinsed in 2xSSC and air dryed.
The slide is then mounted in Vectashield with counterstain added (DAPI or PI).
15 The identification of cells is as described in example 1.
The verification method may alternatively be a diagnostic method using probes rele-vant for the diseases and/or chromosome abnormalities to diagnose.
SUBSTfTUTE SHEET tRULE Z61
The verification method may alternatively be a diagnostic method using probes rele-vant for the diseases and/or chromosome abnormalities to diagnose.
SUBSTfTUTE SHEET tRULE Z61
Claims (28)
1. A method for isolating fetal cells from maternal blood, comprising performing, on a sample of maternal blood having a size of from 0.5 to 44 ml, from which at the most 50 % of the maternal nucleated cells thereof have been removed, and/or at the most 50 % of the maternal anucleated cells have been removed, selective labelling of fetal cells in the maternal blood sample identifying the selectively labelled fetal cells by scanning from 0.5 to 40 ml of the maternal blood sample, and specifically isolating substantially only the selectively labelled fetal cells.
2. The method according to claim 1, wherein the selectively labelled cells are identi-fied by scanning with a scanning rate of from 0.1 m/sec to 10 m/sec.
3. The method according to claim 1, wherein at the most 15 % of the maternal cells thereof have bean removed.
4. The method according to claim 1, wherein at the most 10 % of the maternal cells thereof have been removed.
5. The method according to claim 1, wherein at the most 5 % of the maternal cells thereof have been removed.
6. The method according to claim 1, wherein at the most 2.5 % of the maternal cells thereof have been removed.
7. The method according to claim 1, wherein at the most 1% of the maternal cells thereof have been removed.
8. The method according to claim 1, wherein substantially none of the maternal cells have been removed from the sample.
9. The method according to claim 1, wherein at the most 20% of the maternal nu dented blood cells thereof have been removed.
10. The method according to claim 1, wherein at the most 20 % of the anucleated red blood cells thereof have been removed.
11. The method according to the claim 1, wherein substantially none of the anucle-ated blood sells have been removed from the sample.
12. The method according to claim 1, wherein at the most 20% of the anucleated red blood cells have been removed from the, sample, and at the most 20% of the nucleated blood cells have been removed from the sample.
13. The method according to any of the preceding claims, wherein the maternal blood sample is diluted before labelling or identification of the fetal Cells.
14. The method according to any of the preceding claims, wherein the selective la-belling is based on hybridisation of a probe to m-RNA selectively expressed by fetal cells.
15. The method according to claim 14, wherein the m-RNA is m-RNA coding for a protein selected from the group consisting of embryonic hemoglobin, Such as epsi-lon globin chains and zeta globin chains, and fetal hemoglobin, such as gamma glo-bin chains, and alpha globin chains.
16. The method according to claim 14 or 15, wherein the hybridisation probe is di-rectly labelled by having fluorochromes covalently attached thereto.
17. The method, according to any of claims 1-13, wherein the selective labelling is based on an antigen-antibody reaction with a protein selectively produced by fetal cells.
18. The method according to claim 17, wherein the protein is a protein selected from the group consisting of hemoglobin hemoglobin, such as epsilon globin chains and zeta globin chains, and fetal hemoglobin, such as gamma globin chains and alpha globin chains.
19. The method according to claim 17 or 18, wherein the antibody is selected from anti epsilon (.epsilon.) antibodies, such as monoclonal unlabelled antibodies, and mono-clonal fluorochrome labeled antibodies, anti zeta (~) antibodies, such as monoclonal unlabelled antibodies, monoclonal blown labelled antibodies, monoclonal fluoro-chrome labeled antibodies, and fluorochrome labeled antibodies, anti gamma (.gamma.) antibodies, such as polyclonal (sheep) antibodies, such as monoclonal unlabelled antibodies, monoclonal biotin labelled antibodies, monoclonal fluorochrome labeled antibodies, and fluorochrome labeled antibodies, anti alpha (.alpha.) antibodies, and anti beta (.beta.) antibodies.
20. The method according to any of the preceding claims, wherein two or more se-lective labellings are performed to enhance the probability of identifying the fetal cells in the sample.
21. The method according to Claim 20, wherein a labelling with a hybridisation probe is combined with a antigen-antibody labelling.
22. The method according to any of the preceding claims, wherein the identification of the selectively labelled fetal cells is taking place after spreading the blood sample on a solid surface and detecting labelled cells on the surface.
23. The method according to claim 22 wherein the position of detected labelled cells on the surface is recorded.
24. The method according to claim 23, wherein the detected cells the position of which has been recorded are collected.
25. A method of diagnosing a disease in a fetus comprising obtaining a blood sample having a size of from 0.5 to 40 ml from the woman preg-nant with said fetus, whereby at most 50 % of the maternal nucleated cells have been removed and/or at most 50 % of the maternal anucleated cells have bean re-moved from said blood sample, selective labelling the fetal cells in the maternal blood sample, identifying the selectively labelled fetal cells, by scanning from 0.5 to 40 ml of the maternal blood sample, specifically labelling with at least one disease marker the identified fetal cells for diseases, and identifying specifically labelled cells.
26. The method according to claim 25, wherein the fetal cells are isolated before specifically labelling the fetal cells with at least one disease marker.
27. The method according to claim 25, wherein the disease is a genetic disease and/or a chromosome abnormality.
28. The method according to claim 27, wherein the disease and/or chromosome abnormality is cystic fibrosis, hemophilia, muscular dystrophy, Down' syndrome, Klinefelter, Turner' syndrome.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99201651 | 1999-05-25 | ||
| EP99201651.9 | 1999-05-25 | ||
| PCT/DK2000/000281 WO2000071987A2 (en) | 1999-05-25 | 2000-05-25 | Isolation and culturing of fetal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2413835A1 true CA2413835A1 (en) | 2000-11-30 |
Family
ID=8240233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002413835A Abandoned CA2413835A1 (en) | 1999-05-25 | 2000-05-25 | Isolation and culturing of fetal cells |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU4745200A (en) |
| CA (1) | CA2413835A1 (en) |
| WO (1) | WO2000071987A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2795268A1 (en) | 2009-04-21 | 2010-10-28 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
| WO2011075774A1 (en) | 2009-12-23 | 2011-06-30 | Genetic Technologies Limited | Methods of enriching and detecting fetal nucleic acids |
| US10058306B2 (en) | 2012-06-22 | 2018-08-28 | Preprogen, LLC | Method for obtaining fetal cells and fetal cellular components |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0500727B1 (en) * | 1989-11-13 | 1998-01-21 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal dna |
| US5153117A (en) * | 1990-03-27 | 1992-10-06 | Genetype A.G. | Fetal cell recovery method |
| US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
| US5629147A (en) * | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| AU7921194A (en) * | 1993-09-27 | 1995-04-18 | Oncor, Inc. | Methods for detecting and analyzing individual rare cells in a population |
| US5750339A (en) * | 1994-11-30 | 1998-05-12 | Thomas Jefferson University | Methods for identifying fetal cells |
| US5731156A (en) * | 1996-10-21 | 1998-03-24 | Applied Imaging, Inc. | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
| CN1260046A (en) * | 1997-03-08 | 2000-07-12 | 邓迪大学 | Prenatal diagnostic methods |
| US5962234A (en) * | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
| WO1999041613A1 (en) * | 1998-02-12 | 1999-08-19 | Immunivest | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
-
2000
- 2000-05-25 AU AU47452/00A patent/AU4745200A/en not_active Abandoned
- 2000-05-25 WO PCT/DK2000/000281 patent/WO2000071987A2/en active Application Filing
- 2000-05-25 CA CA002413835A patent/CA2413835A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000071987A3 (en) | 2001-04-19 |
| WO2000071987A2 (en) | 2000-11-30 |
| AU4745200A (en) | 2000-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5629147A (en) | Enriching and identifying fetal cells in maternal blood for in situ hybridization | |
| CA2140278C (en) | Enriching and identyfing fetal cells in maternal blood for in situ hybridization | |
| US5153117A (en) | Fetal cell recovery method | |
| JP6310540B2 (en) | Enrichment and identification of fetal cells in maternal blood and ligands used therefor | |
| EP1172445A1 (en) | A method for direct genetic analysis of target cells by using fluorescence probes | |
| US20030232377A1 (en) | Early noninvasive prenatal test for aneuploidies and heritable conditions | |
| US20050049793A1 (en) | Prenatal diagnosis method on isolated foetal cell of maternal blood | |
| WO1995003431A1 (en) | Enriching and identifying fetal cells in maternal blood for in situ hybridization | |
| WO2008081451A2 (en) | Methods and kits for analyzing genetic material of a fetus | |
| US20100159506A1 (en) | Methods and systems for genetic analysis of fetal nucleated red blood cells | |
| CN111448324A (en) | Cell analysis or improvements related to cell analysis | |
| EP1891204B1 (en) | Method of fetal cell enrichment | |
| WO1995009245A1 (en) | Methods for detecting and analyzing individual rare cells in a population | |
| Hamada et al. | Mid‐trimester fetal sex determination from maternal peripheral blood by fluorescence in situ hybridization without enrichment of fetal cells | |
| CA2413835A1 (en) | Isolation and culturing of fetal cells | |
| CN107312779A (en) | For separate trophocyte aptamer, separate trophocyte method and chromosomal copy number analysis of variance method | |
| US7943304B2 (en) | Method and apparatus for chromosome profiling | |
| US20170152555A1 (en) | Method for detecting presence or absence of heteroploidy of fetal chromosome | |
| US20250027940A1 (en) | Isolation and Diagnostics of Fetal Cells | |
| Chueh et al. | Prenatal diagnosis using fetal cells from the maternal circulation | |
| Babochkina | Fetal cells in maternal circulation: Fetal Cell Separation and FISH Analysis | |
| Bischoff et al. | Prenatal Diagnosis of Chromosomal Abnormalities Using Maternal Blood | |
| WO2001007911A2 (en) | A novel method for the improved isolation of a target cell population |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |